• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Shire prunes San­fil­ip­po A drug af­ter a failed PhI­Ib

9 years ago
R&D

SEC wants to sanc­tion a PwC ac­coun­tant for fail­ing to flag Steven Bur­rill as he loot­ed a biotech fund

9 years ago
Pharma

Mi­croR­NA play­er Mi­Ra­gen bags $40M round and a pub­lic stock list­ing in re­verse merg­er

9 years ago
R&D

Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

9 years ago
R&D

No­var­tis’s block­buster CDK 4/6 con­tender LEE011 gets a VIP count­down at the FDA

9 years ago
Pharma

VIP Clin­ton sup­port­er pitched cam­paign chief Podes­ta on Cana­di­an price con­trols for the US

9 years ago
Pharma

What’s on Sanofi’s M&A list now that Medi­va­tion is gone? Cat­a­lyst gets an SPA; Adap­ti­m­mune part­ners with Mer­ck

9 years ago
News Briefing

NYC’s top re­search in­sti­tu­tions part­ner on Step 2 in build­ing a biotech hub

9 years ago
Startups

2016's drug pric­ing head­winds threat­en a hur­ri­cane of new reg­u­la­tions

9 years ago
Bioregnum
Pharma

Af­ter a se­ries of PI3k pile­ups, Genen­tech of­floads a PhII-ready ri­val for fire­sale price

9 years ago
R&D
Pharma

As­traZeneca R&D leader Pan­ga­los warns of a post-Brex­it UK re­search re­treat with­out re­im­burse­ment re­form

9 years ago
Pharma

In­flu­en­tial Third Rock Ven­tures marks a decade of high-pro­file wins and loss­es with record $616M Fund IV

9 years ago
Financing

Man­u­fac­tur­ing woes de­rail a block­buster con­tender from Sanofi/Re­gen­eron. Who's next?

9 years ago
R&D

Promi­nent MIT sci­en­tist Su­san Lindquist dies of can­cer; Elec­tion fears dam­ag­ing biotech stocks?; Promethera adds 10M ...

9 years ago
News Briefing

An­oth­er Ra­maswamy stunt plays well on Wall Street, Mar­tin Shkre­li on shame, and more

9 years ago
Bioregnum
Opinion

On the ropes, Opexa shares blast­ed by PhI­Ib mul­ti­ple scle­ro­sis tri­al flop

9 years ago
R&D

In­dus­try vet Ken Moch jumps to the helm of a small biotech with big dreams for treat­ing Alzheimer’s

9 years ago
R&D

That En­gMab buy­out? Cel­gene agreed to pay up to $3B for BC­MA-tar­get­ing drug

9 years ago
Deals

FDA flash­es red light on Sanofi man­u­fac­tur­ing in­frac­tion, threat­en­ing a loom­ing block­buster de­ci­sion

9 years ago
Pharma

AS­CO star, backed by bil­lion­aires, goes to Astel­las in $1.4 bil­lion buy­out

9 years ago
Deals

Bil­lion­aire Be­zos, Arch car­ry a torch for ag­ing R&D, back $116M mega-round for Uni­ty

9 years ago
R&D

FDA slaps a par­tial hold on one of As­traZeneca's cru­cial dur­val­um­ab pro­grams

9 years ago
R&D

GSK dumps a late-stage HIV drug; MIT of­fers sup­port for tech start-ups; Ra Phar­ma clos­es flat af­ter $92M IPO

9 years ago
News Briefing

Pro­QR shares spike on pos­i­tive PoC study for lead CF drug

9 years ago
R&D
First page Previous page 1148114911501151115211531154 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.